Scientists at the University of California, San Diego, in La Jolla have found that androgen ablation therapies used to treat prostate cancer may indirectly promote the development of metastatic androgen-independent secondary tumors (Ammirante
M et al. Nature. doi:10.1038/nature08782 [published online ahead of print March 10, 2010]). These tumors are responsible for most deaths due to prostate cancer.
Hampton T. Metastatic Prostate Cancer. JAMA. 2010;303(13):1245. doi:10.1001/jama.2010.351